Biomarkers in chronic graft-versus-host disease
Related Experiment Video
Updated: Jun 1, 2026
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
1Division of Oncology, Hematology and BMT, Department of Pediatrics, BC Children's Hospital/University of British Columbia, Vancouver, BC, Canada.
Insights
Chronic graft-versus-host disease (cGVHD) is a serious complication of stem-cell transplants. Identifying biomarkers could improve diagnosis, treatment response prediction, and understanding of cGVHD.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity following allogeneic hematopoietic stem-cell transplantation.
- Current treatments for cGVHD are often toxic and lack efficacy, highlighting an unmet clinical need.
- Limited understanding of cGVHD pathophysiology hinders effective management.
Purpose of the Study:
- To review existing evidence for candidate biomarkers in cGVHD.
- To explore how these biomarkers may contribute to cGVHD pathophysiology.
- To discuss challenges and opportunities in biomarker discovery and application for cGVHD.
Main Methods:
- Literature review of existing evidence on candidate biomarkers for cGVHD.
- Analysis of biomarker roles in cGVHD pathophysiology.
- Discussion of biomarker discovery and clinical application strategies.
Main Results:
- Candidate biomarkers offer potential for improved diagnosis and treatment monitoring in cGVHD.
- Biomarkers can provide insights into the underlying mechanisms of cGVHD.
- Further research is needed to validate and translate biomarker findings into clinical practice.
Conclusions:
- Biomarker discovery holds significant promise for advancing the clinical management of cGVHD.
- Understanding biomarker origins is crucial for developing comprehensive models of cGVHD pathogenesis.
- Effective biomarker strategies could improve patient outcomes after stem-cell transplantation.
Abstract:
Chronic graft-versus-host disease (cGVHD ) is a leading cause of allogeneic hematopoietic stem-cell transplantation-related mortality and morbidity. It is an immune-mediated disorder that can target almost any organ in the body, often with devastating consequences. The immune-suppressive medications currently used to treat it are equally toxic and are often not very effective. At this time, our understanding of its pathophysiology is limited. The discovery of potential biomarkers offers new possibilities in the clinical management of cGVHD. They could potentially be used for diagnosing cGVHD, for predicting or evaluating response to therapy and for unique insights into the pathophysiology underlying the clinical manifestations of cGVHD. Understanding the biological origins of these biomarkers can help us construct a more comprehensive and clinically relevant model for the pathogenesis of this disease. In this article, we review existing evidence for candidate biomarkers that have been identified in the framework of how they may contribute to the pathophysiology of cGVHD. Issues regarding the discovery and application of biomarkers are discussed.
